Gradientech signs distribution agreement for Europe
The diagnostics company Gradientech today announces an exclusive distribution agreement with Biomedica for the commercialization of QuickMIC® in Austria, Switzerland and Central Eastern Europe.
Biomedica is a leading supplier of In Vitro Diagnostics, Medical Devices and Life Science products for more than 40 years, employing a team of 280 professionals.
“We are very proud to present Biomedica as our first distributor in Europe, a significant milestone for the company and a perfect partner to roll-out the QuickMIC® system in Europe”, says Sara Thorslund, CEO of Gradientech.
“Biomedica is an excellent partner for several reasons. They have solid experience, a complementary product portfolio for sepsis and the significant expertise needed to make the QuickMIC system a market leader for ultra-rapid antibiotic susceptibility testing at their markets”, says Peter Karlberg, VP Sales at Gradientech.
The QuickMIC system’s ultra-rapid and precise results enable patients with sepsis to quickly receive specific personalized guidance of the right antibiotics in the right dose. The modular design makes it flexible and allows hospitals to start on a small scale and then scale up as needed.
“At Biomedica, we aim to meet all our customers’ needs at the highest level. Innovation is one of our core values and adding the product line from Gradientech is a perfect addition to our Sepsis portfolio in that respect. It not only strengthens our position in a strategically important segment where we have major expertise, it also enables to improve clinical decisions in a time sensitive environment”, commented Dr. Petra Wiedemann, Managing Director at Biomedica.
For more information please contact:
Peter Karlberg, VP Sales Gradientech
Tel: + 46 763 29 08 14
Sara Thorslund, PhD, CEO Gradientech
Tel: +46 736 29 35 80
Next-generation antimicrobial susceptibility testingTake a look at our E-book